Source-grounded facts extracted from PHIBRO ANIMAL HEALTH CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Daniel Bendheim was appointed as Chief Executive Officer and President at PHIBRO ANIMAL HEALTH CORP.
“On June 25, 2026, in connection with Daniel (Dani) Bendheim’s appointment to the role of Chief Executive Officer and President of the Company effective July 1, 2026”
PHIBRO ANIMAL HEALTH CORP reported third quarter ended March 31, 2026 results: revenue $383.5 million, net income $24.0 million, EPS $0.59. Guidance reaffirmed.
“guidance for the year ending June 30, 2026. Highlights for the three months ended March 31, 2026 (compared to the three months ended March 31, 2025): - Net sales of $383.5 million, an increase of $35.7 million, or 10% - Net income of $24.0 million, an increase of $3.1 million, or 15% - Diluted earnings per share of $0.59, an increase of $0.08, or 16% -”
PHIBRO ANIMAL HEALTH CORP amended revolving credit of aggregate commitment of $435,000,000 with Coöperatieve Rabobank U.A., New York Branch.
“1, the revolving credit commitment available to the Company under the Original Credit Agreement has increased by $125,000,000, from $310,000,000 to an aggregate commitment of $435,000,000. The foregoing description of Amendment No. 1 does not purport to be complete and is qualified in its entirety by reference to Amendment No. 1, a copy of which has been filed as”
PHIBRO ANIMAL HEALTH CORP amended Amendment No. 1 with Coöperatieve Rabobank U.A., New York Branch valued at $125,000,000 (effective 2026-04-28).
“On April 28, 2026, Phibro Animal Health Corporation (the “Company”) entered into Amendment No. 1 to its Credit Agreement (“Amendment No. 1”) with Coöperatieve Rabobank U.A., New York Branch, as administrative agent, collateral agent and L/C issuer, and each lender from time to time party thereto, which amends the Credit Agreement, dated as of July 3, 2024”
Joyce J. Lee was appointed as Class II director at PHIBRO ANIMAL HEALTH CORP.
“The Board of Directors (the “Board”) of Phibro Animal Health Corporation (the “Corporation”) appointed Joyce J. Lee as a Class II director of the Corporation, effective January 21, 2025.”
Todd Armstrong was appointed as President, North American Region at PHIBRO ANIMAL HEALTH CORP.
“Todd Armstrong, currently serving as Vice President of the US Ruminant Business since 2020, will be promoted to President, North American Region, effective January 1, 2025.”
Rob Aukerman departed as President, North America Region at PHIBRO ANIMAL HEALTH CORP.
“On November 7, 2024, Phibro Animal Health Corporation (the “Company”) was notified by Rob Aukerman that he will be retiring from his position as President, North America Region of the Company effective December 31, 2024.”
PHIBRO ANIMAL HEALTH CORP completed an acquisition involving Zoetis Inc. for $350 million in cash (closed 2024-10-31).
“and Sale Agreement (as amended, modified or supplemented, the “Purchase Agreement”) by and among Phibro and Zoetis. Phibro completed the acquisition at a purchase price of $350 million in cash, subject to certain adjustments set forth in the Purchase Agreement. The Company intends to file an amendment to this Form 8-K to file the financial statements and pro”
PHIBRO ANIMAL HEALTH CORP reported the fiscal year ending June 30, 2024 results: revenue $980 million to $1.020 billion, net income $7 million to $12 million, EPS $0.17 to $0.30.
“We affirm our previously issued fiscal year 2024 guidance for the following measures: – Net sales of $980 million to $1.020 billion – Adjusted EBITDA of $106 million to $112 million – Adjusted net income of $42 million to $47 million – Adjusted diluted EPS of $1.04 to $1.16 – Adjusted effective tax rate of 28% to 30% We have updated our fiscal year 2024 guidance for the following measures: - Net income of $7 million to $12 million - Diluted EPS of $0.17 to $0.30”
PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended March 31, 2024 results: revenue $263.2 million, net income $8.4 million, EPS $0.21.
“Net sales of $263.2 million, an increase of $17.6 million, or 7% - Net income of $8.4 million, a decrease of $1.6 million - Diluted earnings per share of $0.21, a decrease of $0.04”
PHIBRO ANIMAL HEALTH CORP entered into Debt Commitment Letter with Coöperatieve Rabobank U.A., New York Branch, Compeer Financial, PCA, Citibank, N.A. valued at $325 million senior secured incremental first lien term loan facility (effective 2024-04-28).
“Phibro entered into a debt commitment letter (the “Commitment Letter”), dated as of April 28, 2024, with Coöperatieve Rabobank U.A., New York Branch (“Rabobank”), Compeer Financial, PCA (“Compeer”) and Citibank, N.A. (“Citibank” and, collectively with Rabobank and Compeer, the “Commitment Parties”) pursuant to which the Commitment Parties have committed to provide a senior secured incremental first lien term loan facility in an aggregate principal amount of $325 million (the “Incremental Term Facility”).”
PHIBRO ANIMAL HEALTH CORP entered into Purchase and Sale Agreement with Zoetis Inc. valued at $350 million (effective 2024-04-28).
“On April 28, 2024, Phibro Animal Health Corporation, a Delaware corporation (“Phibro Animal Health”), and Phibro Animal Health S.A., a Belgium corporation and wholly-owned subsidiary of Phibro Animal Health (together with Phibro Animal Health, “Phibro”), entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc., a Delaware corporation (“Zoetis”) to acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets (the “Purchased Business”).”
PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended December 31, 2023 results: revenue $249.9 million, net income $1.3 million, EPS $0.03. Guidance reaffirmed.
“guidance for the year ending June 30, 2024. Highlights for the three months ended December 31, 2023 (compared to the three months ended December 31, 2022) - Net sales of $249.9 million, an increase of $5.3 million, or 2% - Net income of $1.3 million, a decrease of $5.9 million - Diluted earnings per share of $0.03, a decrease of $0.15 - Adjusted EBITDA of $29.5”
Richard Johnson changed role as interim Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.
“Mr. Richard Johnson, who has served as Phibro’s interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with Mr. David.”
Glenn C. David was appointed as Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.
“Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024”
PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended September 30, 2023 results: revenue $231.3 million, net income Net loss of $8.0 million, EPS Diluted loss per share of $0.20. Guidance reaffirmed.
“guidance for the year ending June 30, 2024. Highlights for the three months ended September 30, 2023 (compared to the three months ended September 30, 2022) - Net sales of $231.3 million, a decrease of $1.2 million, or 1% - Net loss of $8.0 million, a decrease of $11.9 million - Diluted loss per share of $0.20, a decrease of $0.30 - Adjusted EBITDA of $18.7”
PHIBRO ANIMAL HEALTH CORP shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm at the 2023-11-06 meeting.
“Votes For Votes Against Abstained 219,482,337 878,451 6,815 There were no broker non-votes on this proposal.”
PHIBRO ANIMAL HEALTH CORP shareholders approved Election of three Class I Directors at the 2023-11-06 meeting.
“Director Nominee Votes For Votes Withheld Broker Non-Votes Daniel M. Bendheim 210,829,815 9,062,771 475,017 Jonathan Bendheim 210,428,372 9,464,214 475,017 Sam Gejdenson 206,715,662 13,176,924 475,017”
Richard G. Johnson changed role as Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.
“Richard G. Johnson, the former Chief Financial Officer of the Company, who has been serving as a Finance Advisor to the Company since November 16, 2020, will assume the role of interim Chief Financial Officer until a successor to Mr. Finio is identified.”
Damian Finio departed as Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.
“Damian Finio informed the Company that he will be resigning from his position as Chief Financial Officer of the Company effective September 29, 2023.”
PHIBRO ANIMAL HEALTH CORP updated its the fiscal quarter and fiscal year ended June 30, 2023 guidance (initiated).
“Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter and fiscal year ended June 30, 2023 and its financial guidance for the fiscal year ending June 30, 2024.”
PHIBRO ANIMAL HEALTH CORP incurred term loan of $50,000,000 with Bank of America, N.A., as administrative agent, the 2023 Incremental Term Loan Lenders and the Consenting Lenders at Base Rate for 2023 Incremental Term Loans ranging from 1.00% to 1.75%; Term SOFR maturing April 22, 2026.
“The Second Amendment amends the Existing Credit Agreement to, among other things, (i) incur incremental term loans in an aggregate principal amount of $50,000,000 (the “2023 Incremental Term Loans”) and (ii) add an additional level to the existing Term Loan and Revolving Credit Facility pricing grid.”
PHIBRO ANIMAL HEALTH CORP amended Amended and Restated Credit Agreement, as amended by Amendment No. 2 with Bank of America, N.A. valued at incremental term loans in an aggregate principal amount of $50,000,000 (effective 2023-06-16).
“Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. On June 16, 2023 (the "Amendment No. 2 Effective Date"), Phibro Animal Health Corporation (the "Company") entered into Amendment No. 2 (the "Second Amendment") to that certain Amended and Restated Credit Agreement, dated as of April 22, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified as of the date hereof, the "Existing Credit Agreement," and, as further amended by the Second Amendment, the "Credit Agreement"), among the Company, certain of its subsidiaries acting as guarantors, Bank of America, N.A., as administrative agent, the 2023 Incremental Term Loan Lenders and the Consenting Lenders (each as defined in the Second Amendment).”
PHIBRO ANIMAL HEALTH CORP reported three months ended March 31, 2023 (compared to the three months ended March 31, 2022) results: revenue $245.7 million, net income $10.0 million, EPS diluted EPS of $0.25.
“third quarter and year-to-date ended March 31, 2023. Highlights for the three months ended March 31, 2023 (compared to the three months ended March 31, 2022) - Net sales of $245.7 million, an increase of $6.1 million, or 3% - Net income of $10.0 million, a decrease of $7.6 million, or 43% - Diluted EPS of $0.25, a decrease of $0.19, or 43% - Adjusted EBITDA of”
PHIBRO ANIMAL HEALTH CORP reported financial results for the fiscal quarter ended December 31, 2022.
“On February 8, 2023, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended December 31, 2022.”
Alejandro Bernal was appointed as Class III director at PHIBRO ANIMAL HEALTH CORP.
“appointed Alejandro Bernal as a Class III director of the Corporation, effective February 6, 2023.”
PHIBRO ANIMAL HEALTH CORP reported first quarter ended September 30, 2022 results: revenue $232.5 million, net income $3.9 million, EPS $0.10.
“tax rate for the year ending June 30, 2023. Highlights for the three months ended September 30, 2022 (compared to the three months ended September 30, 2021) - Net sales of $232.5 million, an increase of $17.9 million, or 8% - Net income of $3.9 million, a decrease of $2.7 million, or 41% - Diluted EPS of $0.10, a decrease of $0.07, or 41% - Adjusted EBITDA of”
PHIBRO ANIMAL HEALTH CORP shareholders approved To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2023. at the 2022-11-07 meeting.
“3. Ratification of the Selection of PwC as Independent Registered Public Accounting Firm Votes For Votes Against Abstained 218,748,582 1,824,783 177,848”
PHIBRO ANIMAL HEALTH CORP shareholders approved To approve, on an advisory basis, the compensation of our named executive officers. at the 2022-11-07 meeting.
“2. Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers Votes For Votes Against Abstained Broker Non-Votes 218,928,908 725,200 203,167 893,938”
PHIBRO ANIMAL HEALTH CORP shareholders approved To elect two Class III Directors to serve until the 2025 annual meeting of stockholders and until their successors are duly elected and qualified. at the 2022-11-07 meeting.
“Director Nominee Votes For Votes Withheld Broker Non-Votes Jack C. Bendheim 206,965,740 12,891,536 893,937 E. Thomas Corcoran 216,353,869 3,503,407 893,937”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.